NCT06373991View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 24, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Lupus Erythematosus, Systemic
Interventions
BIOLOGICAL

ATHENA CAR-T

Phase 1 dose escalation (3+3): dose 1 and dose 2.

DRUG

Fludarabine

Intravenous injection of fludarabine.

DRUG

Cyclophosphamide

Intravenous injection of cyclophosphamide.

Trial Locations (1)

471003

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang

Sponsors

Collaborators (1)

Changping Laboratory
All Listed Sponsors
collaborator

The First Affiliated Hospital of Henan University of Science and Technology

OTHER

collaborator

Changping Laboratory

OTHER

lead

EdiGene Inc.

INDUSTRY

NCT06373991 - A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter